Zach Taylor is a business development professional with over 20 years experience in biotech, pharma and medtech industries. He currently serves as Senior Director of Business Development and Strategy for Neon Therapeutics, Inc. (NASDAQ:NTGN). Zach incubated the company as a consultant to Third Rock Ventures, leading diligence and helping create the company business plan culminating in a $55 million Series A financing in 2015. He has since help build the company that was selected to FierceBiotech’s “Fierce 15” in 2016 and was ranked first among small biotechs by the Boston Globe as a Top Place to Work in 2018. Zach was also a key contributor to Neon’s IPO process in 2018. Prior to Neon, Zach held a number of business development roles and strategy roles at companies including Syros Pharmaceuticals, Millennium Pharmaceuticals (acquired by Takeda) and Philips Research in the Netherlands. While at Philips, Zach co-founded Tagworks Pharmaceuticals and helped spin the company out of Philips. Zach holds a BS in Engineering Physics from Cornell University and earned his MBA from the Kellogg School of Business – Northwestern University.